NSE: LALPATHLAB | BSE: 539524

Expensive Performer

Download real time

2793.60 24.50 (0.88%)

26.91% Gain from 52W Low

140.6K NSE+BSE Volume

NSE 02 May, 2025 3:31 PM (IST)

23,352.2

Market Cap

Market Runner Up

0.5

Beta 1Year

Very Low volatility

Dr. Lal Pathlabs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LALPATHLAB, BSE:539524 Dr. Lal Pathlabs Ltd.

Dr. Lal Pathlabs Ltd.

11 Feb 2019

2793.60

0.88%

Q3FY19 Result Update - Q3 in line; Muted Dengue season leads tepid Q3

Accumulate: Dr. Lal Pathlabs Ltd.

Target

Prabhudas Lilladhar

DLPL's revenue, adj. EBITDA and PAT grew 11%, 16% and 27% YoY Change in Estimates | Target | Reco respectively in Q3FY19 and in line with our estimates in margin and earnings. With strong cash flow and growth in new customers and packaged offer, the...

Dr. Lal Pathlabs Ltd. is trading below its 150 day SMA of 2895.4

Dr. Lal Pathlabs Ltd.

25 May 2017

2793.60

0.88%

Dr Lal Pathlabs Ltd Q4FY17 results comment

Results Update: Dr. Lal Pathlabs Ltd.

HDFC Securities

Revenue grew by 5.99% to Rs. 219.9 Cr in Q4FY17 when compared to the previous quarter

Dr. Lal Pathlabs Ltd. has gained 16.43% in the last 1 Month

Dr. Lal Pathlabs Ltd.

23 May 2017

2793.60

0.88%

Dr. Lal Pathlabs - The Right Time to Check-In

Buy: Dr. Lal Pathlabs Ltd.

Target

LKP Securities

growth from ~ 12.0 mn in FY16 to ~ 13.3 mn in FY17 as well as a better sales mix, resulting in improvement in realizations per patient from 660 in FY16 to 688 in FY17. While H1FY17 saw the company's revenues expand at a faster pace where it registered a...

Dr. Lal Pathlabs Ltd. is trading below its 150 day SMA of 2895.4

Dr. Lal Pathlabs Ltd.

03 Jan 2017

2793.60

0.88%

Dr. Lal PathLabs - Healthy Growth Prospects

Buy: Dr. Lal Pathlabs Ltd.

LKP Securities

cardiology tests & services in its quality laboratories which tested over 15.5 mn & 26.3 mn samples and 7.0 mn & 12.0 mn patients in H1 FY17 & FY16 respectively. Indian healthcare industry - a long term structural growth story At just ~ 4.0 % of GDP, India lags in healthcare spends with changes in demographics, increasing incomes, rising penetration of healthcare & medical insurance and opportunities from medical tourism expected to boost demand for the ~ 3.8 tn Indian healthcare delivery industry. This primary demand driver for diagnostic services is expected to grow at ~ 12.0 % CAGR to ~ 6.9 tn by FY20....

Emkay increased Buy price target of Dr. Lal Pathlabs Ltd. to 3100.0 on 26 Apr, 2025.

Dr. Lal Pathlabs Ltd.

07 Dec 2016

2793.60

0.88%

Dr. Lal Path Labs Ltd: Strong growth and margin expansion in... (Dec 07, 2016)

Hold: Dr. Lal Pathlabs Ltd.

Recommendation Target

Karvy

Strong growth and margin expansion in Q2FY17 on YoY basis: The company has grown into a national level lab with a hub-and-spoke model, that handled 15.5 Mn samples in H1FY17. On an average 7.04 Mn patients are depending on DLPL for the trusted accurate results. Post monsoon period,seasonal vector bound fevers like malaria, dengue, chikungunya contributed 2% to the volume growth and 3% to the revenue during the quarter. DLPL posted agood revenue growth of 21.5% YoY to Rs.2622 Mn in Q2FY17.

Dr. Lal Pathlabs Ltd. has gained 16.43% in the last 1 Month

Dr. Lal Pathlabs Ltd.

18 Jul 2016

2793.60

0.88%

Dr. Lal Path Labs Ltd: Strong Position in North India, Expan... (Jul 18, 2016)

Buy: Dr. Lal Pathlabs Ltd.

Karvy

Strong Position in North India, Expanding in South and West Regions: Dr. Lal Path Labs is the second largest diagnostic chain in domestic market with healthy balance sheet and strong cash flows. The company gets 72% of revenue from North India, and is concentrating more on an engagement model between thecompany and the clients. The future acquisitions and partnerships would provide operating synergies and basis for organic growth in these new regions.